IDEXX LABORATORIES INC /DE (IDXX)

IDEXX Laboratories, incorporated in Delaware in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its stated purpose is to create long-term value for customers, employees and stockholders by enhancing the health and well-being of pets, people and livestock.

The company operates through three reportable segments plus an Other category. The Companion Animal Group offers point-of-care diagnostic solutions (the IDEXX VetLab suite of chemistry, hematology, urinalysis, cytology and coagulation analyzers, consumables, and SNAP rapid assay kits), reference laboratory and telemedicine consulting services through a network of about 80 laboratories, and the VetConnect PLUS cloud-based results platform. It also provides veterinary software and diagnostic imaging, including the practice management systems ezyVet, Animana, IDEXX Neo and Cornerstone, ImageVue digital x-ray systems, and the IDEXX Web PACS imaging software, with several products using proprietary AI. The Water segment sells tests such as Colilert, Enterolert, Pseudalert, Legiolert and Filta-Max, along with Quanti-Tray products and Tecta instruments, to detect microbial contaminants. The Livestock, Poultry and Dairy segment sells diagnostics for diseases such as BVDV, PRRS and TSE, pregnancy tests for ruminants, and SNAP tests for antibiotic residues in milk. The Other category covers point-of-care analyzers and consumables for human hospitals and clinics, together with an out-licensing arrangement.

Customers include veterinarians and veterinary practices and corporate groups, pet owners (who receive shared results), biomedical research customers, government and private laboratories, livestock veterinarians, producers and processors, dairy producers, water utilities and certified testing laboratories, and human medical hospitals and clinics. The company sells worldwide, with a sales presence in the U.S., Africa, Asia Pacific, Canada, Europe and Latin America. Its reference laboratory customers are in many developed geographies, including the U.S., Europe, Canada, Australia, Japan, New Zealand, South Africa and South Korea. Sales are made mainly through direct sales forces, supplemented by independent distributors and resellers in certain countries. Canine vector-borne disease test sales are seasonally stronger in the first half of the year.

Some instruments are manufactured by third parties, and the company relies on suppliers, some of them sole or single source, for components, raw materials and consumables. It mitigates this through alternative suppliers, in-house manufacturing capability, escrow arrangements and safety stock. Ortho-Clinical Diagnostics supplies certain Catalyst chemistry slides under agreements running to December 2044, and other supply agreements extend through 2034. IDEXX protects its intellectual property through patents, copyrights, trademarks and trade secrets, and says it faces robust competition. Research and development spending was $251.2 million in 2025, or 5.8% of revenue. The text does not state the location of its headquarters.